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Abstract
The A2b receptor (A2bR) belongs to the adenosine receptor family. Emerging evidence suggest that A2bR is implicated
in tumor progression in some murine tumor models, but the therapeutic potential of targeting A2bR in melanoma
has not been examined. This study first shows that melanoma-bearing mice treated with Bay 60-6583, a selective
A2bR agonist, had increased melanoma growth. This effect was associated with higher levels of immune regulatory
mediators interleukin-10 (IL-10) and monocyte chemoattractant protein 1 (MCP-1) and accumulation of tumor-
associated CD11b positive Gr1 positive cells (CD11b+Gr1+) myeloid-derived suppressor cells (MDSCs). Depletion
of CD11b+Gr1+ cells completely reversed the protumor activity of Bay 60-6583. Conversely, pharmacological block-
ade of A2bR with PSB1115 reversed immune suppression in the tumor microenvironment, leading to a significant
melanoma growth delay. PSB1115 treatment reduced both levels of IL-10 and MCP-1 and CD11b+Gr1+ cell number
in melanoma lesions. These effects were associated with higher frequency of tumor-infiltrating CD8 positive (CD8+)
T cells and natural killer T (NKT) cells and increased levels of T helper 1 (Th1)-like cytokines. Adoptive transfer of
CD11b+Gr1+ cells abrogated the antitumor activity of PSB1115. These data suggest that the antitumor activity of
PSB1115 relies on its ability to lower accumulation of tumor-infiltrating MDSCs and restore an efficient antitumor
T cell response. The antitumor effect of PSB1115 was not observed in melanoma-bearing nude mice. Furthermore,
PSB1115 enhanced the antitumor efficacy of dacarbazine. These data indicate that A2bR antagonists such as PSB1115
should be investigated as adjuvants in the treatment of melanoma.
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Introduction
Adenosine has been described as an important regulator of immune
response in the tumor microenvironment [1,2]. The immune-
suppressive effects of adenosine in tumors are dependent on the
A2a receptor subtype (A2aR), which inhibits T cell functions, favor-
ing tumor development [3]. In contrast, stimulation of A3 adenosine
receptor (A3R) subtype can markedly limit tumor growth by promoting
an efficient antitumor immune response inmice [4,5]. There is growing
evidence that the A2b receptor subtype (A2bR) can also influence tumor
progression in some murine tumor models. We studied the effects
of PSB1115, a selective A2bR antagonist, in a well-established mouse
melanoma model. A2bR is activated by high levels of adenosine [6],
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achieved in hypoxic tumor microenvironments [1]. Ryzhov and col-
leagues [7] provided the first genetic evidence for a pivotal role of
A2bR in tumor development. The growth of Lewis lung carcinoma
was reduced in A2bR-deficient mice compared to that in wild-type con-
trols. This was due to an effect on adenosine-mediated release of angio-
genic factors, such as vascular endothelial growth factor, from host
immune cells [7]. Together with previous evidence on A2bR-mediated
up-regulation of angiogenic factors in cancer cell lines [8,9], these obser-
vations highlight the critical role of A2bR in supporting tumor angio-
genesis. More recently, it has been demonstrated that A2bR promotes
the expansion of myeloid-derived suppressor cells (MDSCs) frommouse
hematopoietic progenitors in vitro [10]. MDSCs contribute to tumor
immune tolerance by releasing adenosine in a CD73-dependent manner
[10,11]. Furthermore, A2bR blockade can reduce the growth of bladder
and breast cancers in mice, by promoting a T cell–mediated response
in a chemokine C-X-C receptor 3 (CXCR3)-dependent manner [12].
These studies suggest that A2bR is implicated in tumor progression
and that blocking A2bR could contribute to improve immune response
in the tumor environment and thus limit tumor growth. Although
our knowledge of the role of A2bR in promoting cancer development
is growing, the antitumor activity of A2bR blockade in melanoma has
not been investigated.
Melanoma is the most aggressive skin tumor, with high metastatic
potential. Advanced melanoma is resistant to most chemotherapeutics
[13]. Immunotherapy has shown promise in preclinical and clinical
studies, and currently, melanoma is one of few malignancies for which
there is a Food and Drug Administration (FDA)-approved immuno-
therapeutic agent, ipilimumab [14–17]. However, in most cases of
advanced melanoma, the prognosis remains dismal, and the current sci-
entific challenge is to further improve the efficacy of melanoma therapy.
The tumor microenvironment is critical to modulate antitumor immune
responses. Immune-suppressive cells in tumormicroenvironment, includ-
ing MDSCs, promote tumor progression by suppressing antitumor
immune responses and/or modulating angiogenesis [18–21]. MDSCs
accumulate in the blood, lymphoid tissue, and tumor tissue, in human
cancers and animal tumor models [18]. MDSCs, identified in mice as
CD11b positive Gr1 positive (CD11b+Gr1+) cells [21], are potent
suppressors of T cell–mediated responses, and strategies aimed at reduc-
ing MDSC accumulation in tumors or suppressing MDSC function
improve T cell activity, resulting in tumor growth inhibition [20,21].
In this study, we show that Bay 60-6583, a selective A2bR agonist,
enhanced melanoma growth by enriching MDSCs in the tumor lesion.
This effect was associated with higher levels of immune-suppressive
mediators such as interleukin-10 (IL-10) andmonocyte chemoattractant
protein 1 (MCP-1). These mediators can further stimulate MDSC
accumulation in the tumor [22–24]. Conversely, administration of
PSB1115 inhibited the accumulation of tumor-infiltrating MDSCs.
This enhanced T helper 1 (Th1)-like response in the tumor environment
and significantly delayed melanoma growth. PSB1115 also increased
the efficacy of melanoma chemotherapeutic dacarbazine in our model.
These results suggest that selective A2bR antagonists such as PSB1115 can
reverse the immune suppression in the tumor environment and poten-
tially enhance the efficacy of melanoma chemo- and immunotherapy.
Materials and Methods
Mice and Cells
Female C57Bl6j and Athymic Nude-Foxn1nu (6-8 weeks old) mice
were purchased from Harlan (Harlan Laboratories, Udine, Italy) and
maintained in a pathogen-free animal facility. All the experiments were
conducted according to institutional animal care guidelines, Italian
DL No. 116 of 27 January 1992, and European Communities Council
Directive of 24 November 1986 (86/609/ECC). B16-F10 murine
melanoma cell line was purchased from American Type Culture Col-
lection (LGC Standards Srl, Milan, Italy) and cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% FBS, L-glutamine
(2 mM), penicillin (100 U/ml), and streptomycin (0.1 mg/ml; Sigma-
Aldrich, Milan, Italy).
In Vivo Studies
For tumor challenge, 2 × 105 B16-F10 cells were subcutaneously
injected on the right flank of anesthetized mice [25]. The specific
adenosine A2bR agonist Bay 60-6583 [26–28] and the selective
A2bR antagonist PSB1115 [26,29,30] were from Tocris Cookson
Ltd (London, United Kingdom). Ten days after tumor cell implanta-
tion, when palpable tumors had developed, Bay 60-6583 (0.2 mg/kg)
or PSB1115 (1 mg/kg) was delivered to the mice for four consecutive
days by the peritumoral (p.t.) route, which is an important route of
administration to evaluate directly the effect of these drugs on tumor
growth. Phosphate-buffered saline alone was used as vehicle control
for PSB1115. Phosphate-buffered saline containing 0.01% DMSO
was used as control for Bay 60-6583. Gemcitabine (Gem, 120 mg/kg;
Sigma-Aldrich) [31,32] was intraperitoneally (i.p.) injected once at day
10 after tumor cell implantation into mice receiving PSB1115 or Bay
60-6583 or vehicle. Dacarbazine (DTIC, 100 mg/kg; Sigma-Aldrich)
[33] was i.p. injected once at day 10 after tumor cell implantation into
mice receiving PSB1115 or vehicle as described above. Mice were killed
the day after the last injection, and melanoma tissues and spleens were
isolated for further analyses. Tumor growth was daily monitored and
calculated as we previously reported [25]. For long-term experiments,
mice were to be killed according to the animal care protocol when the
tumor volume reached ∼1000 mm3.
Isolation and Adoptive Transfer of MDSCs
Spleens of melanoma-bearing mice were digested and passed through
70-μm cell strainers, and red blood cells were lysed. CD11b+Gr1+ cells
were sorted by FACSAria III (BD Biosciences, Milan, Italy; purity was
>92%, as assessed by flow cytometer). An amount of 1.5 × 104 freshly
isolated CD11b+Gr1+ cells was peritumorally injected into melanoma-
bearing mice at day 10 after B16.F10 tumor cell implantation, when
PSB1115 treatment started, as described above.
Flow Cytometry Analysis
Single-cell suspensions from tumors and spleens of treated mice
were prepared for flow cytometry analysis as previously described
[25]. Briefly, tissues were digested and passed through 70-μm cell
strainers, and red blood cells were lysed. Cell samples were pre-
incubated with anti-mouse CD16/CD32 (eBioscience, San Diego,
CA) to block nonspecific Fc-mediated interactions. The following
mouse-specific antibodies were used: CD11c–fluorescein isothio-
cyanate, CD11b-phycoerythrin cyanine 5.5 (PeCy5.5), Gr1-phycoerythrin
(PE) or Gr1-allophycocyanin, CD3-PeCy5.5, CD8-allophycocyanin or
CD8-PE, CD4-allophycocyanin, NK1.1-PE, F4/80-PE, major histo-
compatibility complex II (MHC II)–allophycocyanin, CD80-PE,
CD25-PE, and forkhead box P3 (FoxP3)-PeCy5.5 (all from
eBioscience). Data were acquired with FACSCalibur flow cytometer
(BD Biosciences).
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Intracellular Staining
For intracellular cytokine staining, splenocytes from melanoma-
bearing mice treated with PSB1115 or vehicle (Ctr) were stimulated
with Dynabeads Mouse T-Activator CD3/CD28 (Invitrogen, Milan,
Italy), according to the manufacturer’s instructions, for 20 hours.
Cells were stained with CD3-PeCy5.5 and CD8-allophycocyanin or
CD4-allophycocyanin. After fixation/permeabilization (eBioscience),
cells were then stained with anti-mouse interferon (IFN)-γ–fluorescein
isothiocyanate antibody (Ab). Data were acquired with FACSCalibur
flow cytometer (BD Biosciences). Carboxyfluorescein succimidyl ester
(CFSE) proliferation assay was performed by labeling splenocytes with
1 μMCFSE (eBioscience), cocultured with FACS-sorted CD11b+Gr1+
cells (1:1 ratio), and stimulated with CD3/28 monoclonal antibodies
(mAbs). Flow cytometry analysis of CFSE dilution in CD3+ T cells
was performed on day 5 of culture. Bay 60-6583 was tested at 1 μM.
Enzyme-Linked Immunosorbent Assays
IFN-γ, tumor necrosis factor (TNF), granzyme B, IL-10, andMCP-1
were analyzed by ELISA kits (R&DSystems, Abingdon,UnitedKingdom,
and eBioscience) in melanoma tissue homogenates. IFN-γ levels were
also measured in the supernatant of splenocytes harvested from both
control and PSB1115-treated mice. IL-10 was also measured in the
supernatant of FACS-sorted CD11b+Gr1+ cells stimulated with Bay
(1 μM) for 20 hours.
Statistical Analysis
Results are expressed as means ± SEM. All statistical differences were
evaluated by either two-tailed Student’s t test or one-way analysis of
variance (ANOVA) as appropriate. P values of <.05 were considered
statistically significant.
Results
Bay 60-6583 Promotes Melanoma Growth In Vivo
by Inducing an Immune-Suppressive Environment
in the Tumor Tissue
We first investigated the effect of Bay 60-6583, a selective A2bR
agonist [26–28], on tumor growth in B16 melanoma–bearing mice.
Treatment with Bay 60-6583 (0.2 mg/kg, p.t.) significantly enhanced
melanoma growth compared to control (Figure 1A).
Figure 1. Bay 60-6583 promotes tumor accumulation of MDSCs, which favors melanoma growth. (A) Tumor volumes (mm3) in C57Bl6j
mice treated with Bay 60-6583 (0.2 mg/kg, p.t.) compared to control (Ctr) are expressed as means ± SEM (n = 12 per group). (B) CD11b-
PeCy5.5–positive (+) Gr1-PE+ cells were assessed by flow cytometry in the melanoma lesions from Bay 60-6583–treated and control
mice and expressed as percentage of leukocytes (n = 11 per group). Representative dot plots of tumor-infiltrating CD11b+Gr1+ cells are
shown. CD11b-PeCy5.5+ Gr1-PE+ cells in the melanoma lesions (C) and spleen (D) of tumor-bearing mice received a single injection of
Gem (120 mg/kg, i.p.) and/or Bay 60-6583. Data as percentage are expressed as means ± SEM (n = 12 per group). (E) Tumor volumes
(mm3) in treated and untreated mice (n = 6-10 per group). Data are from three independent experiments and represent means ± SEM.
*P < .05, **P < .01, and ***P < .001 (one-way ANOVA analysis and Student’s t test, as appropriate).
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Because tumor progression can be promoted by an immune-
suppressive environment, we first analyzed immune cell populations
in tumors of Bay 60-6583–treated mice compared to controls. We
found that the percentage of tumor-infiltrating MDSCs, identified
as CD11b+Gr1+ cells [21], was increased in Bay 60-6583–treated
animals compared to control (Figure 1B). There was no change
in FoxP3+CD4+CD25+ T cells (regulatory T cells) in melanoma
lesions of mice treated with Bay 60-6583 compared to controls
(data not shown). To better understand the role of CD11b+Gr1+
cells in Bay 60-6583–induced tumor growth in mice, we depleted
CD11b+Gr1+ cells by using Gem, which preferentially decreases
CD11b+Gr1+ cell levels in tumor-bearing mice as previously reported
by other groups [31,32], most likely by inducing selective death of
Gr1+CD11b+ cells [31]. Gem treatment decreased CD11b+Gr1+ cell
levels both in tumor tissues and in spleens of melanoma-bearing mice
(Figure 1, C and D, respectively, and Figure W1, A and B). More-
over, mice treated with Gem + Bay 60-6583 had decreased numbers
of CD11b+Gr1+ cells both in tumor tissues and in spleens, similar to
Gem alone (Figure 1, C and D, respectively). This effect was associ-
ated with decreased tumor growth compared to control (Figure 1E ).
Notably, treatment of B16.F10 cells in vitro with Gem caused only
∼10% reduction of cell viability (data not shown). Depletion of
CD11b+Gr1+ cells eliminated the increase in tumor volume caused
by Bay 60-6358 (Figure 1E ). Tumor growth in mice receiving
Gem + Bay 60-6583 was not significantly different than those observed
in mice treated with Gem alone (Figure 1E). We also tested whether
Bay 60-6583 could affectMDSC functionality. Bay 60-6583 treatment
in vitro did not affect either the ability of CD11b+Gr1+ cells to suppress
T cell proliferation in a CFSE proliferation assay or the production of
IL-10 (Figure W2, A and B, respectively). These results suggest that
Bay 60-6583 promotes CD11b+Gr1+ cell accumulation in tumor
but did not directly influence their function.
We next investigated Bay 60-6583–mediated effects on inflammatory
factors in melanoma lesions. The levels of IL-10 andMCP-1 were signifi-
cantly increased in the tumor tissue of mice treated with Bay 60-6583
compared with control (Figure 2, A and B, respectively). These inflam-
matory mediators have been reported to be crucial for MDSC accumu-
lation in melanoma tumor lesions [21,24]. Therefore, the increased
number of MDSCs in Bay 60-6583–treated mice is associated with
alteration in inflammatory mediators in the tumor environment.
PSB1115 Arrests Melanoma Growth in Mice
The effect of Bay 60-6583 on melanoma growth was completely
abolished in mice treated with PSB1115 (1 mg/kg, p.t.), a selective
A2bR antagonist [26,29,30] (Figure 3A). Importantly, melanoma
growth was significantly decreased after PSB1115 administration
compared to control mice (Figure 3A). In addition, we performed
long-term experiments where tumor growth was monitored up to
20 days. PSB1115 significantly delayed melanoma growth compared
with control (Figure W3).
We next investigated the mechanism responsible for the antitumor
activity of PSB1115. Because Bay 60-6583 increased the level of
tumor-infiltrating CD11b+Gr1+ cells, we hypothesized that the anti-
tumor activity of PSB1115 was due to inhibition of the accumulation
of CD11b+Gr1+ cells within melanoma tissue. We found that the
number of tumor-infiltrating CD11b+Gr1+ cells of PSB1115-treated
mice was significantly reduced compared to control mice (Figure 3B).
This effect appeared to be selective for CD11b+Gr1+ cells, because the
numbers of CD11c+Gr1− dendritic cells (DCs) or CD11b+Gr1− cells
in tumor tissue were not significantly altered in mice treated with
PSB1115 (Figure W4, A and B, respectively). Administration of
PSB1115 did not affect the maturation of DCs, because the expression
of MHC II and CD80 on DCs was unchanged (Figure W4, C and D,
respectively). The levels of MCP-1 and IL-10 in tumors of mice treated
with PSB1115 were decreased compared to controls (Figure 3, C and
D, respectively), suggesting that the antitumor activity of PSB1115 is
associated with a reduced immune-suppressive tumor environment.
T Cells Contribute to the Antitumor Effect of PSB1115
Numerous studies reported that MDSCs, which are abundant in
melanoma tissue, are potent suppressors of T cell–mediated immune
responses in the tumor milieu [23,34]. We tested whether a reduced
number of CD11b+Gr1+ cells within tumor tissue after PSB1115
administration was associated with improved antitumor immune
response. Mice treated with PSB1115 showed an increased number
of tumor-infiltrating CD8 positive (CD8+) T cells and natural killer
T (NKT) cells (identified as CD3+NK1.1+ cells) in melanoma lesions
compared to controls (Figure 4, A and B). This effect was associated
with increased levels of TNF-α (Figure 4C ), IFN-γ (Figure 4D), and
granzyme B (Figure 4E ) in tumor homogenates compared with
control. We also performed ex vivo experiments on splenocytes of
PSB1115-treated mice. IFN-γ production (Figure 4F ) and the number
of IFN-γ–producing CD8+ T cells and CD4+ T cells (FigureW5,A and
B, respectively) were significantly increased in splenocytes from
PSB1115-treated mice compared with controls.
To elucidate the potential role of nonimmunologic effects in the
antitumor activity of PSB1115, we tested its effects in allograft
tumors in Athymic Nude-Foxn1nu mice. Nude mice, implanted sub-
cutaneously (s.c.) with B16.F10 cells, were treated with PSB1115 as
described above for C57Bl6j mice. No antimelanoma effect of
PSB1115 was observed in nude mice (Figure 4G ), indicating that
the antitumor activity of PSB1115 in our model is entirely due to
immune modulation and underscoring the critical role of T cells in
the antitumor effect of PSB1115.
Taken together, our data indicate that PSB1115 administration had
significant antitumor activity in melanoma-bearing mice. This effect
was associated with reduced accumulation of CD11b+Gr1+ cells in
the tumor environment and increased numbers of tumor-infiltrating
CD8+ T cells and NKT cells, as well as Th1–like cytokine production.
Figure 2. Effects of Bay 60-6583 on immune regulatory mediators
within tumor tissue. IL-10 (A) and MCP-1 (B) levels were analyzed in
tumor tissue homogenates by ELISA as picogram per milligram pro-
tein (n = 7-12 per group). Data are from three independent experi-
ments and represent means ± SEM. *P < .05 (Student’s t test).
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PSB1115 Reduces MDSC Accumulation within
Melanoma Tissue
Our results show that PSB1115 decreases CD11b+Gr1+ cell accu-
mulation within melanoma lesions, leading to reduced tumor growth.
To clarify the role of these cells in the antitumor effect of PSB1115 in
melanoma-bearing mice, we administered PSB1115 in CD11b+Gr1+
cell–depleted mice. Gem was administered at day 10 after B16.F10
cell implantation as reported above. Depletion of CD11b+Gr1+ cells
with Gem did not alter the antitumor activity of PSB1115 com-
pared to mice treated with PSB1115 alone (Figure 5A). The accu-
mulation of CD11b+Gr1+ cells in both tumors and spleens after
treatment with Gem and/or PSB1115 was markedly reduced com-
pared with controls (Figure 5, B and C , respectively). Decreased
accumulation of CD11b+Gr1+ cells was also observed in the spleens
of mice treated with PSB1115 alone (Figure 5C ). However, this
was most likely not due to a systemic effect of PSB1115, which was
peritumorally administered, but a consequence of reduced tumor
volume, consistent with previous studies [35,36]. Indeed, the fre-
quency of CD11b+Gr1+ cells in the spleens of mice of both groups
(PSB1115 and Ctr) with tumors of equal sizes was similar (data
not shown). These data suggest that inhibition of CD11b+Gr1+ cell
recruitment with PSB1115 or depletion of these cells with Gem
have comparable effects on tumor growth and that these effects
are not additive.
Next, to determine whether the antitumor activity of PSB1115
was attributable to impaired accumulation of CD11b+Gr1+ cells
within tumor tissue, we adoptively transferred CD11b+Gr1+ cells
to melanoma-bearing mice receiving PSB1115 or vehicle. Adoptive
transfer of CD11b+Gr1+ cells from tumor-bearing mice abrogated
the antitumor activity of PSB1115 (Figure 5D). The percentage of
tumor-infiltrating CD8+ T cells and NKT cells in mice adoptively
transferred with CD11b+Gr1+ cells and treated with PSB1115 returned
to values similar to those observed in control mice groups (Figure 5,
E and F , respectively).
Figure 3. Effect of PSB1115 on melanoma growth and immune-suppressive mediators in tumors. (A) Tumor-bearing mice were treated
with PSB1115 (1 mg/kg, p.t.), Bay 60-6583, or both, Bay 60-6583 and PSB1115. Tumor volumes (mm3) of treated and untreated mice are
expressed as means ± SEM (n = 12-20 per group). (B) CD11b-PeCy5.5+ Gr1-PE+ cells measured in tumor tissue of control mice and
PSB1115 treated mice are expressed as means ± SEM (n = 11 per group). Representative dot plots of CD11b+Gr1+ cells are shown.
MCP-1 (C) and IL-10 (D) levels as picogram per milligram protein were determined in the tumor tissue homogenate of control mice
or mice treated with PSB1115 and expressed as means ± SEM (n = 12 per group). Results are from three independent experiments.
*P < .05 and ***P < .001 (one-way ANOVA analysis and Student’s t test, as appropriate).
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These results indicate that decreased numbers of tumor-associated
CD11b+Gr1+ cells in PSB1115-treatedmice restored a T cell–dependent
antitumor response and accounted for the reduced melanoma growth.
PSB1115 Treatment Enhances the Therapeutic Efficacy of
the Antimelanoma Chemotherapeutic Dacarbazine
We then explored the therapeutic potential of PSB1115 in com-
bination with dacarbazine, a chemotherapeutic currently used for
treating metastatic melanoma [37]. Dacarbazine (100 mg/kg, i.p.)
[33] alone significantly reduced tumor growth compared to con-
trols (Figure 6A). Interestingly, the combination of dacarbazine
and PSB1115 resulted in enhanced antitumor activity in melanoma-
bearing mice compared to single agents (Figure 6A). The percentage
of CD8+ T cells and NKT cells in the melanoma lesions was signifi-
cantly increased compared with control (Figure 6, B and C , respec-
tively), as well as the levels of granzyme B in tumor tissue (Figure 6D).
Similar results were also obtained in mice treated with oxaliplatin, a
chemotherapeutic not currently used for melanoma therapy (data
not shown).
Discussion
This study shows that A2bR promotes the accumulation of MDSCs in
the melanoma tissue. Hence, the selective A2bR antagonist PSB1115
may be an attractive therapeutic drug to reverse MDSC–mediated
immune suppression and limit melanoma growth.
MDSCs are potent immune regulatory cells that accumulate in
blood, in lymphoid organs, as well as in tumor lesions, in mouse
tumor models, and in patients with cancer [18]. These cells originate
from bone marrow (BM) myeloid progenitor cells and, under nor-
mal conditions, differentiate in peripheral organs into DCs, macro-
phages, or granulocytes [21,23]. In the context of cancer, soluble
Figure 4. T-mediated response is restored in PSB1115-treated mice. (A) CD3-PeCy5.5+CD8-allophycocyanin+ cells and (B) CD3-PeCy5.5
+NK1.1-PE+ cells in tumor tissue from control or treated mice (n = 8-14 per group). Representative dot plots for each population are
shown. TNF-α (C), IFN-γ (D), and granzyme B (E) levels as picogram per milligram protein in the tumor tissue homogenate of treated and
control mice (n = 6-10 per group). Data are expressed as means ± SEM and are from three independent experiments. (F) Splenocytes
isolated from tumor-bearing mice receiving vehicle or PSB1115 were cultured and stimulated with anti-CD3/28 mAbs (black bars). IFN-γ
production was measured in culture supernatants of nonstimulated and stimulated splenocytes by ELISA and expressed as mean ±
SEM (n= 10 per group). (G) Tumor volumes (mm3) were calculated in melanoma-bearing nude mice treated or not treated with PSB1115
(n = 8 per group). Data are from two independent experiments and expressed as means ± SEM. *P < .05, **P < .01 and ***P < .001
(one-way ANOVA analysis or Student’s t test, as appropriate).
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factors released in the tumor microenvironment can inhibit this
maturation process and drive the accumulation of myeloid cells
with immune-suppressive features (MDSCs) [21–24,34]. In mela-
noma mouse models, the production of inflammatory mediators
during tumor progression is thought to attract MDSCs into tumor
lesions [34,36]. These cells markedly impair the proliferation and
functions of T cells, hampering their antitumor activity. Several
lines of evidence indicate that therapeutic strategies that selectively
reduce the number of MDSCs inhibit their function or modulate
their differentiation and can inhibit tumor growth [23,24].
Although the role of many inflammatory mediators in inducing
these processes is well known, recent evidence suggests that adenosine
is also critical in controlling the accumulation of MDSCs in tumor-
bearing mice. It is well established that adenosine accumulates in tissue
under hypoxic conditions typical of tumor microenvironment. Im-
portantly, adenosine can critically hamper the adaptive immune
response [1,2,38,39]. A recent study by Ryzhov et al. demonstrated
that A2bR-deficient mice showed reduced Lewis lung carcinoma tumor
development [10]. Tumor-bearing A2bR−/− mice had lower number
of MDSCs compared with wild-type mice, suggesting a critical role
of this receptor in MDSC expansion [10]. Hence, A2bR stimulation
in BM hematopoietic progenitor cells could prevent their differentia-
tion into mature myeloid cells and thereby promote MDSC accumu-
lation. Moreover, a previous study reported that adenosine, through
A2bR, skews the differentiation of mouse hematopoietic progenitor
cells from DCs toward a tolerogenic, angiogenic, and proinflammatory
phenotype [40]. Expansion of immature myeloid cells in BM of
tumor-bearing animals results in an accumulation of MDSC in periph-
eral lymphoid organs and in the tumor tissue. Our data show that
PSB1115 preferentially decreased the accumulation of tumor-associated
CD11b+Gr1+ cells. We cannot formally exclude the possibility that
PSB1115 might inhibit the differentiation of myeloid progenitor cells
into MDSCs. However, under our experimental conditions in which
PSB1115 was administered peritumorally, a localized inhibitory effect
Figure 5. The antitumor activity of PSB1115 is associated with impaired CD11b+Gr1+ cell accumulation in tumor. (A) Tumor volumes
(mm3) in mice treated with vehicle (Ctr) or PSB1115 and Gem as previously described (n = 7-10 per group). CD11b-PeCy5.5+Gr1-PE+
cells in the tumor tissue (B) or spleen (C) from treated mice are expressed as means ± SEM (n = 6-8 per group). Data are from two
independent experiments. (D) Tumor volumes (mm3) in melanoma-bearing mice receiving PSB1115 or vehicle, adoptively transferred
or not with CD11b+Gr1+ cells, are expressed as means ± SEM (n = 4-5 per group). CD3-PeCy5.5+CD8-allophycocyanin+ cells (E) and
CD3-PeCy5.5+NK1.1-PE+ cells (F) were determined in tumor tissues of treated and untreated mice. Numbers indicate the percentage
of positive cells gated on lymphocyte cells.
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of PSB1115 onMDSC accumulation in the tumormicroenvironment is
more likely. Notably, we did not observe any effect on MDSC accumu-
lation in nontumoral peripheral organs, consistent with an effect
on tumor recruitment rather than with a putative systemic activity of
PSB1115. We cannot rule out that PSB1115 may promote the dif-
ferentiation of MDSCs in macrophages. However, Corzo et al. have
shown that, in tumor microenvironment, MDSCs differentiate prefer-
entially to tumor-associated macrophages [41]. Tumor-associated mac-
rophage promotes tumor growth rather than inhibiting it [41]. The
antitumor activity we have observed in PSB1115-treated mice is not
consistent with this hypothesis. Furthermore, no clear difference was
found for DCs between PSB1115-treated and control mice, suggesting
that PSB1115 does not influence the process of MDSC maturation.
MDSC accumulation in melanoma is driven by soluble factors re-
leased both from tumor and stoma cells [24,34]. Previous reports have
demonstrated that agents able to alter the levels of inflammatory
mediators in tumor microenvironment reduce MDSC accumulation
[36,42,43]. In this work, we found that PSB1115-treated mice showed
reduced concentrations of IL-10 and MCP-1 within tumors. Mela-
noma B16.F10 cells stimulated with Bay 60-6583 in vitro produced
greater amounts of IL-10; this effect was completely blocked by
PSB1115 (data not shown). In our experimental model, the impaired
accumulation of MDSCs in melanoma lesions of mice treated with
PSB1115 might be, at least in part, ascribed to a modulation of
the cytokine milieu in tumor microenvironment from an immune-
suppressive to a nonimmune-suppressive type. To what extent these
inflammatory factors are involved in PSB1115-induced effects in our
model remains to be elucidated in future studies. MDSCs are potent
suppressors of T cell–mediated immune responses in the tumor milieu
[19,23,24]. PSB1115 treatment enhanced the frequency of tumor-
infiltrating CD8+ T cells and NKT cells and the release of IFN-γ com-
pared with controls. When nude mice were used to test the antitumor
activity of PSB1115, we did not observe any effect on melanoma
growth, proving that the activity of PSB1115 was dependent on T cells.
On the basis of our results, we propose that the impaired recruitment
of MDSCs to tumor lesions in PSB1115-treated mice reduces immune
evasion, thereby restoring a T cell immune response. Although our
data support a role for A2bR in mediating MDSC accumulation in
our melanoma model, other receptors may also contribute to the effects
of adenosine. We have previously shown [4,5] that the A3 AR sub-
type has an opposite effect to A2bR. Specifically, activation of A3
by a selective agonist suppresses melanoma growth in an NK- and
CD8 T cell–dependent fashion. Preliminary experiments with A2a
receptor subtype inhibitors indicate that this receptor (which is
highly expressed in T cells) does not modulate MDSC accumulation
but has direct effects on T cells. These results will be reported else-
where. Finally, we showed that the combination of PSB1115 and
dacarbazine was more effective in suppressing melanoma growth than
either drug alone. This data is translationally relevant, as it supports
a possible study of chemoimmunotherapy combination regimens
including standard-of-care chemotherapy with dacarbazine and
immune-stimulatory A2bR antagonists.
The therapeutic potential of A2bR blockade has been tested in few
murine tumor models to date. Cekic et al. [12] demonstrated that
administration of nonselective AR antagonist aminophylline, cur-
rently used for treating respiratory diseases [44,45], can reduce the
Figure 6. PSB1115 enhances the efficacy of dacarbazine against melanoma. (A) Tumor volumes (mm3) of mice receiving dacarbazine
(100 mg/kg, i.p.) and/or PSB1115 are expressed as means ± SEM (n = 7-10 per group). CD3-PeCy5.5+CD8-allophycocyanin+ cells (B)
and CD3-PeCy5.5+NK1.1-PE+ cells (C) were determined in the tumor tissue (n = 6-8 per group). (D) Granzyme B levels as picogram per
milligram protein measured in the tumor tissue homogenate of treated mice are expressed as means ± SEM (n = 6-8 per group). Data
are from two independent experiments. *P < .05, **P < .01, and ***P < .001 (one-way ANOVA analysis).
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growth of bladder and breast cancers in mice in an A2bR-dependent
manner. To our knowledge, this is the first study demonstrating that
selective blockade of A2bR by PSB1115 can be effective in delaying
melanoma growth by inhibiting tumor MDSC accumulation and
restoring antitumor immunity. An interesting question for future
studies is whether A2bR antagonists also increase the efficacy of other
immunotherapeutic strategies in melanoma, such as ipilimumab or
tumor vaccines. As small molecules that presumably have better
tumor penetration than protein-based biologics, A2bR antagonists
may be very attractive candidates for clinical development.
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Figure W1. Gem treatment reduces MDSCs in melanoma-bearing mice. Representative dot plots of CD11b+Gr1+ cells in the tumor (A)
and spleen (B) of mice treated with Gem are compared with control.
Figure W2. (A) Bay 60-6583 did not directly affect the ability of MDSCs to suppress T cell proliferation. (B) IL-10 levels in the super-
natant of CD11b+Gr1+ cells stimulated with Bay 60-6583(1 μM). Data are expressed as means ± SEM and are from two independent
experiments. *P < .05 (one-way ANOVA analysis).
Figure W3. PSB1115 significantly delayed tumor growth compared
with control in long-term experiments. Data are expressed as
means ± SEM. ***P < .001 (one-way ANOVA analysis).
Figure W4. Levels of CD11c+Gr1− cells (A) and CD11b+Gr1− cells
(B) in the tumor tissue of mice treated with PSB1115 are com-
pared with control. Expression of MHC II (C) and CD80 (D) on
tissue DCs of control mice or mice treated with PSB1115. Data
are expressed as means ± SEM and are from three independent
experiments (n = 9 per group).
Figure W5. Representative dot plots of IFN-γ+CD8+ T cells (A) and IFN-γ+CD4+ T cells (B) in cultured splenocytes of mice treated with
PSB1115 or control (Ctr), stimulated with CD3/28 mAbs. Numbers indicate the percentage of positive cells gated on CD3+ cells.
